DE69617699D1 - Neuartige opioid-peptide - Google Patents

Neuartige opioid-peptide

Info

Publication number
DE69617699D1
DE69617699D1 DE69617699T DE69617699T DE69617699D1 DE 69617699 D1 DE69617699 D1 DE 69617699D1 DE 69617699 T DE69617699 T DE 69617699T DE 69617699 T DE69617699 T DE 69617699T DE 69617699 D1 DE69617699 D1 DE 69617699D1
Authority
DE
Germany
Prior art keywords
opioid peptides
new opioid
new
peptides
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69617699T
Other languages
English (en)
Other versions
DE69617699T2 (de
Inventor
Wuyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69617699D1 publication Critical patent/DE69617699D1/de
Application granted granted Critical
Publication of DE69617699T2 publication Critical patent/DE69617699T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1027Tetrapeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69617699T 1995-08-18 1996-08-14 Neuartige opioid-peptide Expired - Fee Related DE69617699T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides
PCT/SE1996/001011 WO1997007130A1 (en) 1995-08-18 1996-08-14 Novel opioid peptides

Publications (2)

Publication Number Publication Date
DE69617699D1 true DE69617699D1 (de) 2002-01-17
DE69617699T2 DE69617699T2 (de) 2003-08-07

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617699T Expired - Fee Related DE69617699T2 (de) 1995-08-18 1996-08-14 Neuartige opioid-peptide

Country Status (27)

Country Link
US (1) US6337319B1 (de)
EP (1) EP0845003B1 (de)
JP (1) JPH11512086A (de)
KR (1) KR19990037677A (de)
CN (1) CN1200127A (de)
AR (1) AR003475A1 (de)
AT (1) ATE210148T1 (de)
AU (1) AU711862B2 (de)
BR (1) BR9610248A (de)
CA (1) CA2229797A1 (de)
CZ (1) CZ287299B6 (de)
DE (1) DE69617699T2 (de)
DK (1) DK0845003T3 (de)
EE (1) EE9800048A (de)
ES (1) ES2171224T3 (de)
HU (1) HUP9901209A3 (de)
IL (1) IL123258A (de)
IS (1) IS4664A (de)
NO (1) NO980592L (de)
NZ (1) NZ315809A (de)
PL (1) PL325113A1 (de)
RU (1) RU2165432C2 (de)
SE (1) SE9503924D0 (de)
SK (1) SK282469B6 (de)
TR (1) TR199800258T1 (de)
TW (1) TW424095B (de)
WO (1) WO1997007130A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2001013938A1 (fr) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
WO2002005748A2 (en) 2000-07-18 2002-01-24 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006132925A2 (en) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (de) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptide und deren Verwendung
AU2007317817B2 (en) 2006-11-10 2012-09-20 Cara Therapeutics, Inc. Synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
KR101690094B1 (ko) * 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) * 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (de) 2013-05-29 2016-04-13 Grünenthal GmbH Manipulationssichere darreichungsform mit einem oder mehreren partikeln
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
NZ315809A (en) 1999-05-28
CZ287299B6 (en) 2000-10-11
HUP9901209A3 (en) 2000-12-28
AU711862B2 (en) 1999-10-21
ES2171224T3 (es) 2002-09-01
JPH11512086A (ja) 1999-10-19
SK282469B6 (sk) 2002-02-05
RU2165432C2 (ru) 2001-04-20
DK0845003T3 (da) 2002-07-15
SE9503924D0 (sv) 1995-11-07
ATE210148T1 (de) 2001-12-15
IL123258A (en) 2003-03-12
PL325113A1 (en) 1998-07-06
TW424095B (en) 2001-03-01
IL123258A0 (en) 1998-09-24
NO980592D0 (no) 1998-02-11
CA2229797A1 (en) 1997-02-27
IS4664A (is) 1998-02-04
TR199800258T1 (xx) 1998-05-21
EE9800048A (et) 1998-08-17
NO980592L (no) 1998-02-11
EP0845003B1 (de) 2001-12-05
CZ40198A3 (cs) 1998-08-12
DE69617699T2 (de) 2003-08-07
BR9610248A (pt) 1999-07-06
HUP9901209A2 (hu) 1999-08-30
CN1200127A (zh) 1998-11-25
WO1997007130A1 (en) 1997-02-27
SK20398A3 (en) 1998-12-02
KR19990037677A (ko) 1999-05-25
US6337319B1 (en) 2002-01-08
EP0845003A1 (de) 1998-06-03
AU6760096A (en) 1997-03-12
AR003475A1 (es) 1998-08-05

Similar Documents

Publication Publication Date Title
DE69617699D1 (de) Neuartige opioid-peptide
DE69620006D1 (de) Sequenzierverfahren
DK0739831T3 (da) Transportør
PT805813E (pt) Antagonistas de vasopressina triciclicos
DK1042359T3 (da) k-Opioidreceptorpeptider
DK0768252T3 (da) Transportør
NO985680D0 (no) Peptidderivater
IS4115A (is) Ný peptíð
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
NO983849L (no) Peptidderivater
FI970168A0 (fi) Peptidejä
FI940109A0 (fi) Peptidejä
BR9609671A (pt) Amino uracilas substituídas
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
NO981051D0 (no) Peptidderivater
FI965116A0 (fi) Uusia opioidipeptidiantagonisteja
BR9510586A (pt) Inflador
FR2732345B1 (fr) Peptide antibacterien
FI950211A (fi) Huokosia muodostavia peptidejä Geolycosa riograndesta
DE59600405D1 (de) Gehhilfe
SE9504467D0 (sv) Peptide
BR1100812A (pt) Peptìdeo
KR970041607U (ko) 자동차의 시동장치
DE69625807D1 (de) Referenzelektrode

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE BIOCHEM INC., LAVAL, QUEBEC, CA

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee